Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ricolinostat for CIPN in breast cancer
NCT05229042Phase 1Completed
- Sponsor
- Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.
- Start
- Jan 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chemotherapy-induced peripheral neuropathy (CIPN) comparing Ricolinostat with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events at 6 months. Started Jan 2022; status: completed.
02
Drugs
ricolinostat
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT05229042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05229042.